(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/136911 A2

(51) International Patent Classification:
C07K 16/32 (2006.01)

(21) International Application Number:
PCT/US2011/031829

(22) International Filing Date:
8 April 2011 (08.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/322,712 9 April 2010 (09.04.2010) US

(71) Applicant *(for all designated States except US)*: **AVEO PHARMACEUTICALS, INC.** [US/US]; 75 Sidney Street, Fourth Floor, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VINCENT, Sylvie** [FR/US]; 1Fitchburg St., C-120, Somerville, MA 02143 (US). **WINSTON, William, M., Jr.** [US/US]; 100 Spoonhill Avenue, Marlborough, MA 01752 (US). **WANG, Fang** [CN/US]; 1Oak Grove Ave., Unit 207, Melrose, MA 02176 (US). **WEILER, Solly** [US/US]; 5 Stony Brae Road, Newton, MA 02461 (US). **MEETZE, Kristan** [US/US]; 519 Elm Street, Walpole, MA 02081 (US). **BREAULT, Lyne** [CA/US]; 71 Dale Street, Roslindale, MA 02131 (US). **BOTEGA, Steve** [CA/US]; 292 Prospect St., Apt. 3, Cambridge, MA 02139 (US). **CHEN, Ting** [US/US]; 20 Central Street, Acton, MA 01720 (US). **DEPRIMA, Michael** [US/US]; 64 Line St., Apt. 2, Somerville, MA 02143 (US). **FLEET, Christina** [US/US]; 306 Main St., #11, Melrose, MA 02176 (US). **TYLER, Steven** [US/US]; 198 Tremont St., #195, Boston, MA 02116 (US). **WOO, Jin-Kyeung** [CN/US]; 118 Withington Road, Newton, MA 02460 (US). **GYURIS, Jeno** [HU/US]; 139 Lexington Road, Lincoln, MA 01773 (US).

(74) Agents: **STERN-DOMBAL, Charlene, A.** et al.; Goodwin Procter LLP, Exchange Place, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/136911 A2

(54) **Title**: ANTI-ERBB3 ANTIBODIES

(57) **Abstract**: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB 3/HER3.